BioSpace News Archive

After its Biologics License Application was rejected by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain levels.

The biotech will supply Canada with fewer doses of its coronavirus vaccine while reaching a financial agreement for the forfeiting of certain doses previously scheduled for delivery.

The biotech has acquired an exclusive global license for Shanghai-based DualityBio’s investigational antibody-drug conjugate for select solid tumors.

The biotech Monday announced a clinical hold on its HEMO-CAR-T candidate, which is being trialed for the treatment of acute myeloid leukemia, due to manufacturing concerns cited by the regulator.

Johnson & Johnson has licensed Nanobiotix’s lead radioenhancer candidate, designed to increase the efficacy of radiation treatment in cancers, capitalizing on the latter’s rocky financial situation.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that Cancer Research Communications has published “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer”.

Hospital for Special Surgery and NCH Healthcare System announced that David L. Helfet, MD, renowned HSS orthopedic trauma surgeon, has been appointed Executive Medical Director of HSS at NCH, the collaboration formed to bring high quality orthopedic care to southwest Florida.

Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ® (daridorexant) CIV on the Performance Drug List (PDL).

The Melanoma Research Alliance announced that the RARE Registry for acral and mucosal melanoma has officially surpassed 100 patients, making it the largest registry of its kind in the world and marking an important milestone in advancing cutting-edge research for these rare and difficult-to-treat melanoma subtypes.

Replicate Bioscience announced today that it has appointed Rachael Lester as its Chief Business Officer.